 NEW YORK, Feb. 25, 2021 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS; Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, announced that it will report its financial results for the fourth quarter and full year ending December 31, 2020, on Thursday, March 4, 2021, after the close of the US market. The announcement will be followed by a conference call at 8:00 AM EST 2:00 PM CET on Friday, March 5, 2021, prior to the open of the US market. 